Technology Networks: Addressing Key Limitations in Disease Models

At the European Laboratory Research and Innovation Group’s (ELRIG) Drug Discovery 2024 event, our CTO Chris Saunter was asked how Magnitude Bioscience’s technology addresses key limitations in traditional disease models, along with a selection of start-up companies featured in the conference’s Breakthrough Zone.

“Traditional cell models struggle with two key challenges: translatability and the inability to model aging. Cells – except for certain types like fibroblasts – don’t naturally age, limiting their usefulness in studying age-related diseases. Mammalian models, while more predictive, are costly and can take months or years to generate the same data.”

“Our [Magnitude Biosciences] Caenorhabditis elegans (C. elegans) platform addresses both of these limitations. The worms have a lifecycle of just three days, and have a total lifespan of two-three weeks, allowing us to rapidly test compounds for their effects on aging and longevity. This offers a significant advantage over traditional models, both in terms of cost and speed. We believe that our scalable, whole-organism approach will play a pivotal role in the future of disease modeling, particularly in aging research, where there’s a growing need for faster and more predictive models.”

Read the full article: https://www.technologynetworks.com/tn/blog/biotech-start-ups-share-how-they-are-addressing-key-limitations-in-disease-models-392269

Related Resources

• Article

2024 Trends & Predictions: Gut Health, Mood, and Market Innovation

2024 Trends & Predictions: Gut Health, Mood, and Market Innovation...Read More

• Article

Personal Care Magazine: Developing Efficient Probiotics in Ageing

Personal Care Magazine: Developing Efficient Probiotics in Ageing...Read More

• Article

Technology Networks: Addressing Key Limitations in Disease Models

Technology Networks Feature: Addressing Key Limitations in Disease Models...Read More

• Leaflet

Brochure: Pharma & Biotech

Brochure: Pharma & Biotech - read and download the brochure...Read More

• Article
• Resources

IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening With C. elegans

IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening W...Read More

• Blog Post
• Resources
• Video

Magnitude Biosciences Podcast Ep 1 | Dr Alex Parker: Screening probiotics to treat ALS with C. elegans

Magnitude Biosciences Podcast Ep 1 | Dr Alex Parker: Screening probiotics to treat ALS with worms...Read More

• Blog Post
• Resources

The Nematode Corner: Delaying Forgetting – How Ice and Lithium Affect Memory in C. elegans

Delaying Forgetting - How Ice and Lithium Affect Memory in C. elegans...Read More

• Blog Post
• Resources

The Nematode Corner: Toxicity Testing with C. elegans

Welcome back to “The Nematode Corner” where we explore the fascinating world of Caenorha...Read More

• Leaflet

Brochure: Health & Nutrition

Brochure: Health & Nutrition - read and download the brochure...Read More

• Blog Post
• Resources

Probiota 2024: Exploring Probiotic Efficacy Beyond CFUs

A couple of weeks ago we attended Probiota 2024 in Milan, a global meeting to discuss the science an...Read More

• Case Study

Case Study: Identifying a lead candidate for slowing ageing with Gerostate Alpha

GeroState Alpha is a pharmaceutical company, based at the Buck Institute for Research on Ageing in N...Read More

• Case Study

Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio

Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to deve...Read More

• Blog Post
• Resources

The Nematode Corner: Unearthing Nutraceutical Discoveries

Welcome back to “The Nematode Corner,” where we continue our journey into the extraordin...Read More

• Blog Post
• Resources

The Nematode Corner: Powering Industry Progress

Welcome to the fascinating world of C. elegans, a microscopic nematode worm that holds the key to un...Read More

• Case Study
• Resources

Case Study – AB Biotek works with Magnitude Biosciences to accelerate probiotic development

We help our partners in the nutraceuticals & ingredients industry uncover and validate the diver...Read More

• Blog Post
• news
• Resources

Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease

Lundbeck collaborates with Magnitude on innovate platform to test neurodegenerative disease interven...Read More

• Podcast

Tiny Worms- Experiments Fast

David Weinkove, CEO of Magnitude Biosciences joins New Matter ...Read More

• Case Study

Case Study: Michelin & Magnitude Biosciences

Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufactur...Read More

• Poster

ELRIG Drug Discovery 2021

Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans&nb...Read More

• news
• Publication

Frontiers in Aging: Applying C. elegans to industrial drug discovery

Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More

• Video

C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research

Magnitude Bioscience CEO, David Weinkove, discusses the application of C. elegans to accelerate the ...Read More

• Poster

Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans

Check out our poster showing how we can quantify the efficacy of neurodegeneration models...Read More

• Video

C. elegans mobility decline

This video shows an automated method to quantify that decline developed by Magnitude Biosciences whi...Read More

• Publication

Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety

Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control sati...Read More

• Publication

Chemosensory Neurons Modulate the Response to Oomycete Recognition in Caenorhabditis elegans

The Barkoulas Lab, including our own Michael Fasseas , find an Oomycetes recognition response in&nbs...Read More

• Webinar

UK SPINE Recording

Our CEO, David Weinkove, discusses the use of C. elegans and how they could be used in the...Read More

• Webinar

Microbiome SIG Webinar Series

Our CEO, Dr. David Weinkove, explains how healthspan readouts can be used to understand mechanisms i...Read More

• Video Poster

Automated Imaging of C. elegans for Ageing, Neurodegeneration and Behaviour

How large scale non-invasive imaging of C. elegans to enable reliable measurement of Agein...Read More

• Publication

C. elegans Automated Imaging Platform

Magnitude Biosciences presentation from ELRIG online 2020 on the use of C. elegans in pre-...Read More

• Poster

C. elegans Automated Imaging in Drug Discovery

De-risking drug candidates ahead of rodent studies with a non-mammalian model for ageing, neurodegen...Read More

• Publication
• Resources

An overview of the use of C. elegans in longevity research including the genetic manipulation of animals.

An overview of the use of C. elegans in longevity research including the genetic manipulat...Read More